NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -92.18M | -16.65M | -39.01M | -93.77M | -49.50M |
| Total Depreciation and Amortization | 51.00K | 28.00K | 19.00K | 15.00K | 13.00K |
| Total Amortization of Deferred Charges | -227.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.85M | 4.09M | -406.00K | 49.29M | 7.07M |
| Change in Net Operating Assets | -7.98M | 28.00K | -14.59M | -10.14M | 9.34M |
| Cash from Operations | -37.48M | -12.50M | -53.98M | -54.60M | -33.07M |
| Capital Expenditure | -3.00K | -75.00K | -209.00K | -385.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.18M | -- | -- | -- | -- |
| Cash from Investing | -62.18M | -75.00K | -209.00K | -385.00K | -3.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 456.64M | 58.00K | 4.66M | 398.38M | 0.00 |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -989.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.00K | 0.00 | 0.00 | -515.00K | -- |
| Cash from Financing | 456.61M | 58.00K | 4.66M | 198.18M | 0.00 |
| Foreign Exchange rate Adjustments | -7.94M | 4.54M | -909.00K | -2.50M | 5.22M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 349.01M | -7.98M | -50.44M | 140.70M | -27.86M |